Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744891 | 1.00 | PPARD (0.56) | PPARDPPARGPPARAAPEX1POLB | |
| SCHEMBL1744570 | 1.00 | PPARD (0.56) | PPARDPPARGPPARAAPEX1POLB | |
| SCHEMBL1244040 | 0.97 | PPARD (0.58) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744320 | 0.95 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744315 | 0.95 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744318 | 0.95 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1746487 | 0.94 | PPARD (0.65) | PPARDPPARGPPARAAPEX1 | |
| Mavodelpar SCHEMBL1746567 | 0.94 | PPARD (0.55) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744830 | 0.94 | PPARD (0.55) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744825 | 0.94 | PPARD (0.55) | PPARDPPARGPPARAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | VTV THERAPEUTICS LLC (US) | 2025-11-27 | — | — | US | claimed |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| CN-114727976-A | Use of PPAR-delta agonists in the treatment of renal disease | 雷内奥制药公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| CN-113747891-A | Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) | 雷内奥制药公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113710683-A | Use of PPAR-delta agonists in the treatment of mitochondrial myopathy | 雷内奥制药公司 | 2021-11-26 | — | — | CN | claimed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | claimed |
| EP-3756661-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | vTv Therapeutics LLC (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2020-07-09 | — | — | US | claimed |
| WO-2015035171-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-03-12 | — | — | WO | claimed |
| US-20150072985-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | VTVX HOLDINGS I LLC | 2015-03-12 | — | — | US | claimed |
| US-20140024645-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-01-23 | — | — | US | claimed |
| US-8551993-B2 | Phenoxy acetic acids as PPAR delta activators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-08 | — | — | US | claimed |
| US-20130102610-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | claimed |
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | claimed |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | VTVX HOLDINGS II LLC | 2009-04-09 | — | — | US | claimed |
| EP-1979311-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072985-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | PPARA, PPARD, PPARG | PPARD 2/4885PPARG 3/4885PPARA 1/4885 |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | PPARA, PPARG, PPARD | PPARD 3/4885PPARG 2/4885PPARA 1/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | PPARD 1/4885PPARG 4/4885PPARA 2/4885 |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20130102610-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20140024645-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | PPARD 1/4885PPARG 4/4885PPARA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.